Physician profile
Deirdre M Collins
NPI 1780793430
$7,267.00
in general payments reported to CMS, 2019-2025
13 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,489 · 2021: $105 · 2022: $37.48 · 2023: $106 · 2024: $364 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $6,372.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $352.48 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $140.74 | 2019-2024 | Jynarque |
| Amgen INC. | $62.16 | 2019-2021 | |
| Travere Therapeutics, INC. | $61.80 | 2024 | |
| Boston Scientific Corporation | $54.46 | 2024 | Exalt Model D |
| Lilly USA, LLC | $41.88 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $41.05 | 2024-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $39.84 | 2025 | Wegovy |
| Vifor Pharma, INC. | $39.22 | 2021-2024 | |
| Glaxosmithkline, LLC. | $24.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.38 | 2025 | |
| Opko Pharmaceuticals, LLC | $16.79 | 2024 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.